Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells

Maria S. Pino, Steffan T. Nawrocki, Francesco Cognetti, James L. Abruzzese, Henry Q. Xiong, David J. McConkey

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) is constitutively expressed in most human primary carcinomas and with its synthesized product, prostaglandin E2 (PGE2), appears to play important roles in tumor invasion, angiogenesis, resistance to apoptosis and suppression of host immunity. However, the molecular mechanisms that control COX-2 expression are unclear. The purpose of this study was to clarify the mechanism of basal and PGE2- mediated COX-2 expression in the highly metastatic L3.6pl human pancreatic cancer cell line. Using RNA interference to disrupt the expression of CREB and the NF-κB p65 subunit, we found that both are involved in maintaining basal COX-2 expression in L3.6pl cells. We also demonstrated that PGE 2 increased the cyclic AMP concentration, thereby activating protein kinase A (PKA), which in turn phosphorylated the cyclic AMP response element binding protein (CREB), leading to interaction with the cyclic AMP response element in the promoter region of the COX-2 gene. Immunocytochemical analysis confirmed that PGE2 stimulated the translocation of PKA to the nucleus and increased the immuno-reactivity of phosphorylated CREB. Pretreatment with the PKA selective inhibitor H 89 and the E-prostanoid receptor 2 inhibitor AH 6809 reduced COX-2 upregulation by PGE2. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay results further suggested a role for CREB in COX-2 transcriptional control. Understanding the pathways that control COX-2 expression may lead to a better understanding of its dysregulation in pancreatic carcinomas and facilitate the development of novel therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1263-1269
Number of pages7
JournalCancer Biology and Therapy
Volume4
Issue number11
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Response Elements
Cyclooxygenase 2
Pancreatic Neoplasms
Dinoprostone
Cyclic AMP
Cyclic AMP Response Element-Binding Protein
Cyclic AMP-Dependent Protein Kinases
Chromatin Immunoprecipitation
Electrophoretic Mobility Shift Assay
RNA Interference
Prostaglandins E
Genetic Promoter Regions
Prostaglandins
Immunity
Up-Regulation
Apoptosis
Carcinoma
Cell Line
Genes

Keywords

  • cAMP
  • COX-2
  • CREB
  • EP
  • Pancreatic cancer
  • PGE
  • PKA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pino, M. S., Nawrocki, S. T., Cognetti, F., Abruzzese, J. L., Xiong, H. Q., & McConkey, D. J. (2005). Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biology and Therapy, 4(11), 1263-1269.

Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. / Pino, Maria S.; Nawrocki, Steffan T.; Cognetti, Francesco; Abruzzese, James L.; Xiong, Henry Q.; McConkey, David J.

In: Cancer Biology and Therapy, Vol. 4, No. 11, 11.2005, p. 1263-1269.

Research output: Contribution to journalArticle

Pino, MS, Nawrocki, ST, Cognetti, F, Abruzzese, JL, Xiong, HQ & McConkey, DJ 2005, 'Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells', Cancer Biology and Therapy, vol. 4, no. 11, pp. 1263-1269.
Pino, Maria S. ; Nawrocki, Steffan T. ; Cognetti, Francesco ; Abruzzese, James L. ; Xiong, Henry Q. ; McConkey, David J. / Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. In: Cancer Biology and Therapy. 2005 ; Vol. 4, No. 11. pp. 1263-1269.
@article{1711a5d2ce1446a4932946d86f1855a4,
title = "Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells",
abstract = "Cyclooxygenase-2 (COX-2) is constitutively expressed in most human primary carcinomas and with its synthesized product, prostaglandin E2 (PGE2), appears to play important roles in tumor invasion, angiogenesis, resistance to apoptosis and suppression of host immunity. However, the molecular mechanisms that control COX-2 expression are unclear. The purpose of this study was to clarify the mechanism of basal and PGE2- mediated COX-2 expression in the highly metastatic L3.6pl human pancreatic cancer cell line. Using RNA interference to disrupt the expression of CREB and the NF-κB p65 subunit, we found that both are involved in maintaining basal COX-2 expression in L3.6pl cells. We also demonstrated that PGE 2 increased the cyclic AMP concentration, thereby activating protein kinase A (PKA), which in turn phosphorylated the cyclic AMP response element binding protein (CREB), leading to interaction with the cyclic AMP response element in the promoter region of the COX-2 gene. Immunocytochemical analysis confirmed that PGE2 stimulated the translocation of PKA to the nucleus and increased the immuno-reactivity of phosphorylated CREB. Pretreatment with the PKA selective inhibitor H 89 and the E-prostanoid receptor 2 inhibitor AH 6809 reduced COX-2 upregulation by PGE2. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay results further suggested a role for CREB in COX-2 transcriptional control. Understanding the pathways that control COX-2 expression may lead to a better understanding of its dysregulation in pancreatic carcinomas and facilitate the development of novel therapeutic approaches.",
keywords = "cAMP, COX-2, CREB, EP, Pancreatic cancer, PGE, PKA",
author = "Pino, {Maria S.} and Nawrocki, {Steffan T.} and Francesco Cognetti and Abruzzese, {James L.} and Xiong, {Henry Q.} and McConkey, {David J.}",
year = "2005",
month = "11",
language = "English (US)",
volume = "4",
pages = "1263--1269",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells

AU - Pino, Maria S.

AU - Nawrocki, Steffan T.

AU - Cognetti, Francesco

AU - Abruzzese, James L.

AU - Xiong, Henry Q.

AU - McConkey, David J.

PY - 2005/11

Y1 - 2005/11

N2 - Cyclooxygenase-2 (COX-2) is constitutively expressed in most human primary carcinomas and with its synthesized product, prostaglandin E2 (PGE2), appears to play important roles in tumor invasion, angiogenesis, resistance to apoptosis and suppression of host immunity. However, the molecular mechanisms that control COX-2 expression are unclear. The purpose of this study was to clarify the mechanism of basal and PGE2- mediated COX-2 expression in the highly metastatic L3.6pl human pancreatic cancer cell line. Using RNA interference to disrupt the expression of CREB and the NF-κB p65 subunit, we found that both are involved in maintaining basal COX-2 expression in L3.6pl cells. We also demonstrated that PGE 2 increased the cyclic AMP concentration, thereby activating protein kinase A (PKA), which in turn phosphorylated the cyclic AMP response element binding protein (CREB), leading to interaction with the cyclic AMP response element in the promoter region of the COX-2 gene. Immunocytochemical analysis confirmed that PGE2 stimulated the translocation of PKA to the nucleus and increased the immuno-reactivity of phosphorylated CREB. Pretreatment with the PKA selective inhibitor H 89 and the E-prostanoid receptor 2 inhibitor AH 6809 reduced COX-2 upregulation by PGE2. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay results further suggested a role for CREB in COX-2 transcriptional control. Understanding the pathways that control COX-2 expression may lead to a better understanding of its dysregulation in pancreatic carcinomas and facilitate the development of novel therapeutic approaches.

AB - Cyclooxygenase-2 (COX-2) is constitutively expressed in most human primary carcinomas and with its synthesized product, prostaglandin E2 (PGE2), appears to play important roles in tumor invasion, angiogenesis, resistance to apoptosis and suppression of host immunity. However, the molecular mechanisms that control COX-2 expression are unclear. The purpose of this study was to clarify the mechanism of basal and PGE2- mediated COX-2 expression in the highly metastatic L3.6pl human pancreatic cancer cell line. Using RNA interference to disrupt the expression of CREB and the NF-κB p65 subunit, we found that both are involved in maintaining basal COX-2 expression in L3.6pl cells. We also demonstrated that PGE 2 increased the cyclic AMP concentration, thereby activating protein kinase A (PKA), which in turn phosphorylated the cyclic AMP response element binding protein (CREB), leading to interaction with the cyclic AMP response element in the promoter region of the COX-2 gene. Immunocytochemical analysis confirmed that PGE2 stimulated the translocation of PKA to the nucleus and increased the immuno-reactivity of phosphorylated CREB. Pretreatment with the PKA selective inhibitor H 89 and the E-prostanoid receptor 2 inhibitor AH 6809 reduced COX-2 upregulation by PGE2. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay results further suggested a role for CREB in COX-2 transcriptional control. Understanding the pathways that control COX-2 expression may lead to a better understanding of its dysregulation in pancreatic carcinomas and facilitate the development of novel therapeutic approaches.

KW - cAMP

KW - COX-2

KW - CREB

KW - EP

KW - Pancreatic cancer

KW - PGE

KW - PKA

UR - http://www.scopus.com/inward/record.url?scp=33646431435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646431435&partnerID=8YFLogxK

M3 - Article

C2 - 16319525

AN - SCOPUS:33646431435

VL - 4

SP - 1263

EP - 1269

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 11

ER -